Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
Key facts
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Kunming, Qingdao, Shanghai, Shenyang, Ürümqi, Wuhan, and Xi'an, ChinaSee the 15 sites
Where in China
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaContact: Guangzhi ZhaoTaking people
- Navy General Hospital, BeijingBeijing, ChinaContact: Jing WangTaking people
- Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Yuhu HeTaking people
- Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Xiangwei Liu, DoctorTaking people
- HuaXi hospitalChengdu, ChinaContact: Jun Shi, DoctorTaking people
- Army Medical Center of PLAChongqing, ChinaContact: Gengze Wu, DoctorTaking people
- Fujian Provincial Hospital Affiliated to Fuzhou UniversityFuzhou, ChinaContact: Xinjing Chen, PhDTaking people
- Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Xianbao Liu, DoctorTaking people
- Fuwai Yunnan Cardiovascular HospitalKunming, ChinaContact: Da Zhu, PhDTaking people
- Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Weili LiuTaking people
- Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Yu ZhuangTaking people
- The General Hospital of Northern Theater CommandShenyang, ChinaContact: Yang LiTaking people
- People's Hospital of Xinjiang Uygur Autonomous RegionÜrümqi, ChinaContact: Xiangyu DongTaking people
- Renmin Hospital of Wuhan UniversityWuhan, ChinaContact: Jing Chen, DoctorTaking people
- The First Affiliated Hospital of Air Force Medicial UniversityXi'an, ChinaContact: Rutao Wang, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT07267117
- Record updated
- 5 December 2025
- Original description
The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.Read full original descriptionShow less
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease (VALVE-COMPASS)
The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.
Inclusion: At least 18 years old; Be willing and able to provide informed consent to participate in the study; Patients with heart valve disease diagnosed by echocardiography who meet one of the following criteria:; Grade II or higher Aortic valve regurgitation: regurgitant jet width >3 mm, jet width / LVOT diameter ≥25%, jet cross-sectional area/LVOT cross-sectional area ≥5%, effective regurgitant orifice area (EROA) ≥0.1 cm², regurgitant volume per beat (R Vol)≥30 ml, or regurgitant fraction (RF) ≥30%; Moderate or higher aortic valve stenosis: peak velocity ≥3.0 m/s, Mean gradient ≥20 mm Hg, aortic valve area ≤1.5 cm², Indexed aortic valve area ≤0.85 cm²/m², or velocity ratio ≤0.50; Grade II or higher mitral valve regurgitation: regurgitant jet width ≥3 mm, regurgitant volume per beat ≥30 ml, regurgitant jet area/left atrial area >30%, or effective regurgitant orifice area (EROA) ≥0.2 cm²; Moderate or higher valve stenosis: valve area (specific finding) ≤1.5 cm², or mean gradient (supportive finding) ≥10.0 mmHg; Grade II or higher tricuspid valve regurgitation: regurgitant jet width ≥3 mm, proximal isovelocity surface area ≥6 mm, effective regurgitant orifice area (EROA) ≥0.2 cm², or regurgitant volume per beat ≥30 ml; Significant tricuspid valve stenosis: mean pressure gradient ≥5.0 mmHg, inflow time-velocity integral >60 cm, T1/2 ≥190 ms, or valve area ≤1.0 cm²; Grade II or higher pulmonary valve regurgitation: regurgitant jet width >3 mm, regurgitant volume per beat ≥30 ml, regurgitant fraction ≥30%, or effective regurgitant orifice area (EROA) ≥0.1 cm²; Moderate or higher Pulmonary valve stenosis: pulmonary valve transvalvular pressure gradient ≥40 mmHg, right ventricular systolic pressure ≥60 mmHg, or pulmonary valve opening <1.5 cm².
Exclusion: Patients who cannot cooperate with information collection and follow-up due to mental illness or other conditions; Patients whose life expectancy is less than 12 months due to non-cardiac diseases (such as cancer, liver disease, kidney disease, or end-stage lung disease); Patients who are unwilling to accept registration and follow-up.